Author:
Abulaiti Mosha,Yalikun Yaxiaer,Murata Kozue,Sato Asako,Sami Mustafa M.,Sasaki Yuko,Fujiwara Yasue,Minatoya Kenji,Shiba Yuji,Tanaka Yo,Masumoto Hidetoshi
Abstract
Abstract
Human iPS cell (iPSC)-derived cardiomyocytes (CMs) hold promise for drug discovery for heart diseases and cardiac toxicity tests. To utilize human iPSC-derived CMs, the establishment of three-dimensional (3D) heart tissues from iPSC-derived CMs and other heart cells, and a sensitive bioassay system to depict physiological heart function are anticipated. We have developed a heart-on-a-chip microdevice (HMD) as a novel system consisting of dynamic culture-based 3D cardiac microtissues derived from human iPSCs and microelectromechanical system (MEMS)-based microfluidic chips. The HMDs could visualize the kinetics of cardiac microtissue pulsations by monitoring particle displacement, which enabled us to quantify the physiological parameters, including fluidic output, pressure, and force. The HMDs demonstrated a strong correlation between particle displacement and the frequency of external electrical stimulation. The transition patterns were validated by a previously reported versatile video-based system to evaluate contractile function. The patterns are also consistent with oscillations of intracellular calcium ion concentration of CMs, which is a fundamental biological component of CM contraction. The HMDs showed a pharmacological response to isoproterenol, a β-adrenoceptor agonist, that resulted in a strong correlation between beating rate and particle displacement. Thus, we have validated the basic performance of HMDs as a resource for human iPSC-based pharmacological investigations.
Funder
AMED
RIKEN BDR Organoid Project
Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. 1Causes of death, 2000–2016, Global Health Estimates (GHE), World Health Organiation (WHO).
https://www.who.int/healthinfo/global_burden_disease/estimates/en/
. Accessed on 3rd October, 2020.
2. Packer, M. et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349–1355 (1996).
3. 3The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9–13, (1999).
4. Kotecha, D. et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 384, 2235–2243 (2014).
5. Metra, M. & Teerlink, J. R. Heart failure. Lancet 390, 1981–1995 (2017).
Cited by
97 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献